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ABSTRACT 
A simple stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of 
Osimertinib Mesylate in tablet dosage forms. Reversed-phase chromatography was performed on Shimadzu Model CBM-20A/20 Alite, using a 
mixture of 0.1% T.E.A and methanol (50:50, v/v) as mobile phase with a flow rate of 1.0 mL/min.  Detection was carried at 211n m. Linearity 
was observed over the concentration range of 10–400 μg/mL (R2 = 0.9992) with regression equation y = 125927x + 192648 Osimertinib 
Mesylate was subjected to stress conditions (acidic, alkaline, oxidation and thermal degradation) and validated as per ICH guidelines. The 
validated method can be applied to perform long-term and accelerated stability studies of Osimertinib Mesylate formulations.  
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1. INTRODUCTION 
Osimertinib Mesylate (recently known as mereletinib; 
exchange name Tagrisso) is a drug used to treat non little cell 
lung carcinomas with an explicit change. It is a third-age 
epidermal development factor receptor tyrosine kinase 
inhibitor. Created by astrazeneca, the prescription was 
affirmed as a malignancy treatment in 2017 by both the 
nourishment and medication organization and the European 
commission. 
 
Figure 1: Chemical structure of Osimertinib Mesylate 
 
 
Osimertinib Mesylate is a little atom tyrosine kinase receptor 
inhibitor and antineoplastic operator that is utilized in the 
treatment of chose types of cutting edge non-little cell lung 
malignant growth (NSCLC). Osimertinib Mesylate is related 
with a moderate rate of serum aminotransferase rises amid 
treatment and uncommon cases of clinically obvious intense 
liver damage. 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents:  
HPLC grade Methanol (Merck), Tri Ethyl Amine (Merck), 
sodium acetate trihydrate (Merck), Hydrochloric acid 
(Rankem), sodium hydroxide (Rankem), Hydrogen peroxide 
(Rankem) was used. Osimertinib Mesylate, obtained as a gift 
sample from Sun Pharmaceutical Industries Ltd., (India), was 
used. 
Osimertinib Mesylate is available with brand name Tagrisso 
(80 mg of the drug per tablet; Wellness Pharma 
International) were purchased from the local market.  
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2.2. Instrumentation and conditions:  
Chromatographic separation was achieved by using a 
Shimadzu Mode.000l CBM-20A/20 Alite HPLC system, 
equipped with SPD M20A prominence photodiode array 
detector with Phenomenex C8 (250 mm × 4.6 mm i.d., 5 µm 
particle size) column kept up at 25 ºC.  
2.3. Preparation of stock solution: 
Osimertinib Mesylate stock solution (1000 μg/mL) was 
prepared by weighing accurately 10 mg of OSM in a 10 mL 
volumetric flask with methanol. Working standard solutions 
were prepared on daily basis from the stock solution with 
methanol. 
2.4. Preparation of 0.1% TEA: 
1mL of Tri Ethyl Amine was dissolved in HPLC grade water 
in a 1000 mL volumetric flask (pH 3.90). 
Isocratic elution was performed using 1.0% Tri Ethyl Amine 
and methanol (50:50, v/v). The overall run time was 10 min. 
and the flow rate was 1.0mL/min. 20 µL of sample was 
infused into the HPLC system.  
3. METHOD VALIDATION  
The method was validated for system suitability, linearity, 
and limit of quantitation (LOQ), limit of detection (LOD), 
precision, accuracy, selectivity, and robustness.  
3.1. Linearity: 
Linearity test solutions for the assay method were set up 
from a stock solution at various concentration levels (10– 
400 μg/mL) of the assay analyte concentration and 20 µL of 
each solution was infused into the HPLC system and the 
obtained peak area region from the chromatogram was 
noted. The calibration curve was plotted by taking the 
concentration on the x-axis and the relating peak area on the 
y-axis. The data were treated with linear regression analysis 
method. The limit of quantification and limit of detection 
depended on the standard deviation of the response and the 
slope of the constructed calibration curve (n=3), as described 
in ICH guidelines Q2 (R1) 6.  
3.2. Precision and accuracy: 
The intra-day precision of the assay method was evaluated 
by carrying out 6 independent assays of a test sample of OSM 
at three concentration levels (10, 20 and 50 μg mL) (n=3) 
against a qualified reference standard. The %RSD of three 
acquired assay values at three diverse concentration levels 
was determined. The inter-day precision study was 
performed on three different days i.e. day-I, day-II and day-
III at three different concentration levels (10, 20 and 50 
μg/mL) and each value is the average of three 
determinations (n=3). The % RSD of the three obtained assay 
values on three different days was calculated. The accuracy 
of the assay method was assessed in triplicate at three 
concentration levels (50, 100 and 150%), and the percentage 
recoveries were determined. Standard addition and recovery 
experiments were conducted to determine the accuracy of 
the method for the quantification of OSM in the drug product. 
The study was carried out in triplicate at 50, 100 and 150 
μg/mL. The percentage of recovery in each case was 
calculated. 
3.3. Robustness: 
The robustness of the assay method was established by 
providing small changes in the HPLC conditions which 
included wavelength (206 and 216 nm), the percentage of 
methanol in the mobile phase (48 and 52%) and flow rate 
(0.9 and 1.1 mL/min). Robustness of the method was studied 
utilizing six replicates at a concentration level of 100 μg/mL 
of OSM. 
3.4. Assay of marketed formulations (Tablets): 
Solutions were also prepared by extracting the marketed 
formulations (Tablets) with the methanol and filtered. The 
filtrate so obtained was diluted as per the requirement and 
20 µL solution of each of the marketed formulations 
(Tagrisso®) was injected into the HPLC system and from the 
calibration curve, the percentage recovery was calculated.   
3.5. Forced degradation studies:  
Forced degradation studies were performed to assess the 
stability indicating properties and specificity of the method. 
All solutions for stress studies were prepared at an initial 
concentration of 100µg/mL of OSM and refluxed for 2 hours 
at 60 ºC and then diluted with methanol.   
100µg/mL of OSM solution was exposed to acidic 
degradation with 0.1 M HCl for 2 hours at 60 ºC the stressed 
sample was cooled, neutralized and diluted with methanol. 
Similarly, stress studies were conducted in alkaline 
conditions with 0.1 M NaOH at 60 ºC for 2 hours and 
neutralized after cooling with proper dilution with methanol.  
Oxidative stress studies were performed using 30 % H2O2 
and thermal stress studies were conducted in the thermostat 
at 60 ºC for 2 hours. 20 µL solution of each of the solutions 
under forced degradation studies were infused into the HPLC 
system and the chromatograms were recorded from which 
the percentage recovery and also the degradants were 
studied. 
4. RESULTS AND DISCUSSION  
Initially, the stressed samples were analyzed using a mixture 
of 0.1% TEA and methanol (65:45, v/v). with a flow rate of 
0.9 mL/min in which the resolution and peak symmetry was 
not satisfactory. The flow rate was changed to 1 mL/min and  
the drug sample was injected into the loop where a sharp 
peak was eluted at 3.048 minutes with tailing. Finally, the 
mobile phase composition was modified as 50:50, v/v and 
the drug peak eluted were sharp and symmetrical (UV 
detection at 211 nm) with retention time less than 5 minutes 
(2.17 ± 0.03 min). Osimertinib Mesylate shows linearity over 
a concentration range of 0.1–400 μg/mL (Table 1) with % 
RSD 0.03-0.69. The linear regression equation was found to 
be y = 145681x + 110238 (R2 = 0.9997). The LOQ was found 
to be 0.0647μg/mL and the LOD was found to be 
0.0931μg/mL. The % RSD range was obtained as 0.24-0.56 
and 0.16-0.72 for intra-day and inter-day precision studies 
respectively (Table 2). 99-100.02 % of recovery was 
observed in the accuracy studies with % RSD 0.46-0.68 (<2.0 
%) (Table 2). 
Table 1: Linearity of Osimertinib Mesylate 
Conc. Mean peak area   ± SD %RSD 
0.5 517774 ± 551 0.10 
1 297878 ± 434 0.14 
5 736709 ±  513.5 0.69 
10 1469918 ± 4528.5 0.30 
20 2718987 ± 2642 0.09 
30 4082112 ± 7594.5 0.18 
50 6368697 ± 2541 0.03 
80 10288450 ± 30482 0.29 
100 12905061 ± 82600 0.64 
*Mean of three replicates
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Table 2: Precision and accuracy studies of Osimertinib Mesylate 
Conc. 
(µg/mL) 
Intra-day precision Inter-day precision 
* Mean peak area ± SD (% RSD) * Mean peak area ± SD (% RSD) 
10 1483496 ± 4747.18  (0.32) 1494269 ± 2390.83 (0.16) 
20 2721896 ± 6532.55 (0.24) 2739617 ± 4931.31 (0.18) 
50 6378120 ±  35717.74  (0.56) 6387120 ± 45987.26 (0.72) 
Accuracy 
Spiked conc. 
(µg/mL) 
Total conc. 
(µg/mL) 
* Mean peak area ± SD (% RSD) 
Drug Found 
(µg/mL) 
% Recovery 
5 (50 %) 15 2211669 ± 10173.67 (0.46) 14.85 99 
10 (100 %) 20 2726354 ± 18539.20 (0.68) 20.04 100.2 
15(150 %) 25 3407942 ± 18402.88 (0.54) 24.91 99.64 
*Mean of three replicates 
 
The robustness of an analytical procedure refers to its 
capacity to stay unaffected by small or deliberate variations 
in method parameters and gives an indication of its 
reliability for routine analysis. The robustness of the method 
was evaluated by testing a similar sample under various 
analytical conditions deliberately changing from the first 
condition. The outcomes obtained (Table 3) from the assay 
of the test solutions were not influenced by varying the 
conditions and were as per the results for unique conditions. 
The % RSD value of assay for a similar sample under original 
conditions and robustness conditions was under 2.0% (0.59-
1.23) showing that the developed method was robust. 
The representative chromatogram, 3D Curves of Osimertinib 
Mesylate were shown in Figure 2, 3. The proposed method 
was applied to the marketed formulations (TAGRISSO®) and 
the percentage recovery was 100.76-101.61 (Table 4) 
without the interference from the excipients used in these 
tablets.
 
 
Figure 2: Typical chromatograms of Osimertinib Mesylate Standard Drug (10 μg ml-1). 
 
Figure 3: Typical 3D curves of Osimertinib Mesylate (a) Standard Drug (10 μg ml) 
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Table 3: Robustness study of Osimertinib Mesylate 
Parameter Condition *Mean peak area ± SD (% RSD) 
Flow rate 
(± 1.0 mL/min) 
0.9 
1433872 ± 17636.62 
 
(1.23) 1.0 
1.1 
Detection wavelength 
(± 5 nm) 
 
206 
 1483963 ± 8755.38 
 
(0.59) 211 
216 
Mobile phase composition 
(0.1% acetic acid: methanol) 
(± 2 %, v/v) 
48:52 
1463789 ± 9368.24 
 
(0.64) 50:50 
52:48 
*Mean of three replicates 
Table 4: Analysis of Osimertinib Mesylate commercial formulation (Tablets) 
Sample No. Formulation Labeled claim (mg) *Amount found   (mg) *Recovery (%) 
1 Brand I 400 393.65 101.61 
1 Brand II 800 793.94 100.76 
*Mean of three replicates 
 
The stability indicating the capability of the method was 
established from the separation of OSM peak from the 
degraded samples. The degradation of OSM was found to be 
very similar for both the tablets and standard. Typical 
Chromatogram 3D curves and chromatograms obtained 
following the assay of stressed samples is shown in Figure 
4A-D, 5A-5D, respectively. A slight decomposition was seen 
on exposure of OSM drug solution to acidic (0.62%), alkaline 
(1.76%), oxidative (7.37%) and thermal (1.83%) conditions. 
The degradants were observed at 3.099, 2.944, 2.763 and 
2.795 min were observed. The percentage of drug 
degradation was less than 10% in all stressed conditions 
indicating that Osimertinib Mesylate is very much resistant 
(Table 5). 
The present stability-indicating method for the 
determination of OSM in pharmaceutical formulations is 
specific because the drug peak was well separated even in 
the presence of degradation products. Also, Osimertinib 
Mesylate is more resistant towards all degradations and the 
overall data demonstrated that the excipients and the 
degradation products did not interfere with the OSM peak. 
The system suitability parameters for the OSM peak shows 
that the theoretical plates were more than 2000 and the 
tailing factor was less than 2 (Table 5). 
 
 
 
(a)  
 
(b) 
 
(c) 
 
(d) 
Figure 4: Typical Chromatograms of Osimertinib Mesylate (10μg/ml) on (a) Acidic degradation, (b) Alkaline degradation, (c) 
Oxidative degradation and (d) Thermal degradation.  
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Table 5: Forced degradation studies of Osimertinib Mesylate 
Stress Conditions 
*Retention 
time 
*Drug 
recovered 
(%) 
*Drug 
decomposed 
(%) 
Theoretical 
plates 
Tailing 
factor 
Standard drug (Untreated) 3.048 100 - 7548.15 1.320 
Acidic degradation 1 ml 0.1N HCl, 80°C, 30 mins 3.099 99.38 0.62 11110.044 1.310 
Alkaline degradation 0.1 ml 0.1N NaOH, 80°C, 30 mins 2.944 98.24 1.76 9231.985 1.319 
Oxidative degradation 1 ml 3% H2O2, 80°C, 30 mins 2.763 92.63 7.37 2764.708 0.905 
Thermal degradation 
105°C, 30 mins 
2.795 98.17 1.83 3108.060 1.289 
*Mean of three replicates 
 
5. CONCLUSION 
The proposed stability-indicating HPLC method was 
validated as per ICH guidelines and applied for the 
determination of Osimertinib Mesylate in pharmaceutical 
dosage forms and can be successfully applied to perform 
long-term and accelerated stability studies of Osimertinib 
Mesylate formulations.  
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Figure 5: Typical 3D Curves of Osimertinib Mesylate (10μg/ml) on (a) Acidic degradation, (b) Alkaline degradation, (c) 
Oxidative degradation and (d) Thermal degradation. 
